TQB-3617

N/A

Report date: 2024/01/09 13:51:33
NME

Base Information

Drug NameTQB-3617
Drug Alias NameTQB3617胶囊TQB-3617CT-4460
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsPrimary MyelofibrosisEsophageal Squamous Cell CarcinomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary Myelofibrosis
Inactive IndicationsEsophageal Squamous Cell CarcinomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A